PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-135566 | Pharmaceuticals And Medical
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Pharma Contract Manufacturing Organisations (Cmos) for Injectable Drug Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET
7.1 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA PHARMA CONTRACT MANUFACTURING ORGANISATIONS (CMOS) FOR INJECTABLE DRUG MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Catalant
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Boehringer Ingelheim
16.3 Lonza AG
16.4 Grifols International SA
16.5 AbbVie Inc
16.6 Patheon Inc
16.7 Vetter
16.8 Aenova Group
16.9 Almac Group
16.10 Pharmaceutical Product Development
16.11 CMIC Group
16.12 Nectar Lifesciences
16.13 WuXi AppTec
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeBlood Factors
Cytokines
Peptide Hormone
Immunoglobulin
Monoclonal Antibodies (mAbs)
Insulin
Other Drug Classes
By Application
Pharma Company
Biotech Company
Companies
Catalant
Boehringer Ingelheim
Lonza AG
Grifols International SA
AbbVie Inc
Patheon Inc
Vetter
Aenova Group
Almac Group
Pharmaceutical Product Development
CMIC Group
Nectar Lifesciences
WuXi AppTec
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.